Skip to main content

Table 1 Patient Demographic and Clinicopathologic Characteristics

From: Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: Interim results of a prospective cohort study

Characteristic MIMS Trial study group (n = 489) Peripheral blood (n = 215) Bone marrow (n = 177)
Age    
   Mean (St. Dev.) 56.8 (11.4) 56.3 (10.9) 56.3 (10.8)
   Range 26, 89 29, 84 30, 83
Race    
   Caucasian 421 (86.1%) 180 (83.7%) 157 (88.7%)
   Black 61 (12.5%) 31 (14.4%) 18 (10.2%)
   Other 7 (1.5%) 4 (1.9%) 2 (1.1%)
Primary Tumor    
   T1 334 (68.3%) 146 (67.9%) 117 (66.1%)
   T2 145 (29.7%) 63 (29.3%) 52 (29.4%)
   T3 10 (2.1%) 6 (2.8%) 8 (4.5%)
Histologic Grade    
   I 133 (27.2%) 63 (29.3%) 53 (29.9%)
   II 195 (39.9%) 89 (41.4%) 66 (37.3%)
   III 136 (27.8%) 54 (25.1%) 49 (27.7%)
Nodal Metastases (H&E)    
   N0 344 (70.4%) 150 (69.8%) 127 (71.8%)
   N1 145 (29.7%) 64 (29.8%) 49 (27.7%)
Nodal Metastases (PCR)    
   N0 251 (51.3%) 116 (54.0%) 94 (53.1%)
   N1 238 (48.7%) 96 (44.7%) 80 (45.2%)
Clinical Stage:    
   I 267 (54.6%) 120 (55.8%) 97 (54.8%)
   IIA 138 (28.2%) 55 (25.6%) 47 (26.6%)
   IIB 69 (14.1%) 33 (15.4%) 25 (14.1%)
   IIIA 11 (2.3%) 7 (3.3%) 8 (4.5%)
   IIIB 2 (0.4%) 0 (0%) 0 (0%)
   IV 2 (0.4%) 0 (0%) 0 (0%)
ER Status    
   ER-neg 107 (21.9%) 46 (21.4%) 42 (23.7%)
   ER-pos 360 (73.6%) 154 (71.6%) 122 (68.9%)
PR Status    
   PR-neg 156 (31.9%) 67 (31.2%) 58 (32.8%)
   PR-pos 284 (58.1%) 120 (55.8%) 85 (48.0%)
Her2neu Status    
   Her2neu-neg 218 (44.6%) 115 (53.5%) 91 (51.4%)
   Her2neu-pos 89 (18.2%) 42 (19.5%) 30 (16.9%)
Histologic Type    
   Infiltrating Ductal 394 (80.6%) 167 (77.7%) 140 (79.1%)
   Infiltrating Lobular 44 (9.0%) 18 (8.4%) 16 (9.0%)
   Other 50 (10.2%) 30 (14.0%) 21 (11.9%)
Risk Category    
   Low Risk 53 (10.8%) 23 (10.7%) 16 (9.0%)
   Intermediate Risk 50 (10.2%) 11 (5.1%) 13 (7.3%)
   High Risk 386 (78.9%) 181 (84.2%) 148 (83.6%)